Latest news with #ResearchTrianglePark
Yahoo
09-07-2025
- Politics
- Yahoo
EPA workers in RTP among those put on leave for criticizing Trump, Zeldin policies
Environmental Protection Agency workers in Research Triangle Park are among those the agency has put on administrative leave for signing a letter criticizing EPA Administrator Lee Zeldin. At least six Triangle staff members are currently on leave, says Holly Wilson, an EPA employee and president of the American Federation of Government Employees Local 3347, which represents area agency workers. These employees will be paid but are barred from all agency duties through July 17, 'pending an administrative investigation,' according to an internal EPA email sent on July 3 and reviewed by The News & Observer. The agency confirmed it placed 139 workers on leave last week after they signed a letter addressed to Zeldin, which accused his administration of 'recklessly undermining the EPA mission' in five areas, including 'undermining public trust' and 'ignoring scientific consensus to benefit polluters.' The petition was hosted on the website of Stand Up For Science, a nonprofit advocacy group launched in February to protest federal funding cuts under President Donald Trump. While some EPA employees signed the dissent letter anonymously, others entered their names. In a statement Monday, the EPA said it 'has a zero-tolerance policy for career bureaucrats unlawfully undermining, sabotaging, and undercutting the administration's agenda as voted for by the great people of this country last November.' The agency also said the workers on leave represented 'a small fraction' of the EPA's total workforce. Zeldin, a former Republican congressman from Long Island, was confirmed to lead the environmental agency shortly after President Trump retook office. In May, he said his agency aimed to lower spending by $300 million and reduce employment to its 1980s level. Entering the new Trump administration, the EPA had more than 15,000 total employees, down from more than 17,000 workers in 2010. The EPA said the employees on leave had included their agency positions when signing the petition, which could have given the impression they were acting in their professional capacities. Yet Wilson argues signing the letter was a protected act of free speech. 'The mildest dissent should not be met with fear and intimidation,' she said. 'Staff are within their rights to engage with management when they have concerns. In fact, it is their duty.' In a statement Monday, the American Federation of Government Employees demanded the return of all EPA workers on leave and said it planned 'to protect its members to the fullest extent of the law and our contract.' The EPA campus in Research Triangle Park focuses on air-quality regulations and is the agency's biggest site. More than 2,000 full-time federal employees and contractors reported to its facilities, as of last year. This site also housed a significant portion of the agency's scientific research division, called the Office of Research and Development, which the Trump administration has proposed reorganizing into a smaller Office of Applied Science and Environmental Solutions. 'Dismantling the Office of Research and Development' was one of the five concerns EPA staff listed in their dissent letter.
Globe and Mail
07-07-2025
- Business
- Globe and Mail
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. 'Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and increasing value that continues well into the next decade,' said Jon Stonehouse, chief executive officer of BioCryst. Previously, Mr. Ghias was executive vice president of investments and portfolio management at Paragon Biosciences, a global biotech development firm. He also served as chief financial and operating officer for several Paragon portfolio companies. At Paragon, he launched four biotechnology companies focused on rare diseases from early clinical to successful commercial launch. From 2014 to 2017, he served as CFO and head of corporate development at Marathon Pharmaceuticals, a specialty rare disease company, where he prepared the company for a commercial launch and led the successful sale of the firm. Mr. Ghias has raised over $1 billion in capital for the companies he has been involved with. Earlier in his career, for over a decade, he was an investment banker who served as a senior member of the mergers and acquisitions team at Credit Suisse, providing strategic advice to clients and boards of directors in the healthcare and life sciences industries and successfully closing over $80 billion in transactions. 'I am thrilled to join BioCryst at such a pivotal time in its growth journey. The strong commercial momentum from ORLADEYO alongside the advancing pipeline and the opportunity to deploy capital behind new growth initiatives present an enormous opportunity for building long term value. I look forward to partnering with the leadership team to drive operational excellence and financial discipline, and support our ambitious growth plans,' Ghias said. Mr. Ghias earned his M.B.A. with honors from Washington University in St. Louis and holds a B.S. in economics from Lahore University of Management Sciences in Pakistan. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding future results, performance, achievements, plans and expectations regarding BioCryst's growth, capital deployment, and pipeline. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst's ability to successfully progress its pipeline development plans; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst's ability to successfully commercialize its products and product candidates; BioCryst's ability to successfully manage its growth and compete effectively; timing for achieving and sustainability of profitability and positive cash flow may not meet management's expectations; statements regarding financial goals and the attainment of such goals may differ from actual results based on market factors and BioCryst's ability to execute its operational, capital deployment and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst's projections and forward-looking statements. BCRXW
Yahoo
03-07-2025
- Business
- Yahoo
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the 'Company'), today announced that, on June 30, 2025, it granted equity awards to two new non-executive employees as a material inducement to employment. The equity awards were granted under the Company's 2021 Inducement Plan, as amended, and were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards consisted of stock options to purchase an aggregate of 240,000 shares of the Company's common stock and 150,000 restricted stock units ('RSUs'). The stock options have an exercise price of $0.94, which is equal to the closing price of the Company's common stock on the grant date of June 30, 2025. The options vest over a period of four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in equal quarterly installments at the end of each quarter thereafter. The RSUs vest in four equal installments on the first, second, third and fourth anniversary of the grant date. All equity awards are subject to the employees' continued employment with the Company on the applicable vesting dates. About Opus Genetics The Company is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. The Company is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances. The Company is based in Research Triangle Park, NC. For more information, visit ContactsInvestorsJenny KobinRemy BernardaIR Advisory Solutionsir@ MediaKimberly HaKKH Source: Opus Genetics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
03-07-2025
- Science
- New York Times
E.P.A. Employees Are Invited to Adopt Soon-to-Be Homeless Lab Rats
Employees at the Environmental Protection Agency's research campus in North Carolina are preparing to take on a new responsibility. Bring home lab rats as pets. Or maybe some zebra fish. Both animals have long been used at the E.P.A. facility to test the toxicity of chemicals. But as the E.P.A. shuts down its research arm as part of the Trump administration's deep cuts to government scientific work, the animals need new homes. So employees at the agency's sprawling Research Triangle Park in North Carolina have set up an adoption plan, according to four people with knowledge of the program. Staff members can take home the rats or fish and keep them as pets. 'Adopt love. Save a life,' read a poster displayed on campus last week, according to a picture obtained by Public Employees for Environmental Responsibility, a nonprofit that provides legal assistance to government workers who speak out on environmental issues. 'Would you like to adopt?' According to an email sent Tuesday by Maureen R. Gwinn, acting assistant administrator of E.P.A.'s Office of Research and Development, the program has started accepting applications, though adoptions were on a temporary hold as the agency considered the adoption criteria. The E.P.A. works with about 20,000 animals, one of the people said, a vast majority of which are fish or fish larvae. Two rabbits also remained on the North Carolina campus until recently, the person said, but they have now been adopted. Want all of The Times? Subscribe.
Yahoo
01-07-2025
- Business
- Yahoo
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025
RESEARCH TRIANGLE PARK, N.C., July 01, 2025--(BUSINESS WIRE)--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants can connect to the call using the information provided in the confirmation email and will be placed directly into the call. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit IQVIAFIN View source version on Contacts Kerri Joseph, IQVIA Investor Relations ( Alissa Maupin, IQVIA Media Relations ( Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
